Feb 1 (Reuters) - Syndax Pharmaceuticals Inc:
* SYNDAX ANNOUNCES IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION WITH ASTRAZENECA
* SYNDAX PHARMACEUTICALS INC - CO & ASTRAZENECA TO COLLABORATE ON NON-EXCLUSIVE BASIS TO EVALUATE COMBINATION OF TWO DRUGS IN MULTIPLE SOLID TUMOR TYPES
* SYNDAX PHARMACEUTICALS INC - SYNDAX EXPECTS TO INITIATE A PHASE IB STUDY IN FIRST HALF OF 2018
* SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED Source text for Eikon: Further company coverage: